What is the mortality rate for patients with Child-Pugh class A compensated liver cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Mortality Rate of Child-Pugh Class A Liver Cirrhosis

The annual mortality rate for Child-Pugh class A compensated cirrhosis is approximately 4% per year, with 6-year survival reaching 54% in compensated patients. 1, 2

Natural History and Mortality Data

The mortality rate for Child-Pugh class A cirrhosis varies based on whether patients remain compensated or develop decompensation:

Compensated Disease Mortality

  • Annual mortality rate: 4.0% per year in patients with compensated hepatitis C-related cirrhosis 1
  • 6-year survival: 54% for compensated cirrhotic patients overall 2
  • Mortality increases to 5.7% annually when other potential causes of liver disease coexist, compared to 3.6% in those without additional liver insults 1

Perioperative Mortality in Child-Pugh Class A

  • 90-day postoperative mortality: 2.1% following surgery under general anesthesia 3
  • Cardiac surgery mortality: approximately 3% (1 of 31 patients) in Child-Pugh class A patients 4
  • Elective joint arthroplasty mortality: 6% (9 of 158 patients) within 2 years for Child-Pugh class A 5

Causes of Death

The dominant causes of mortality in Child-Pugh class A cirrhosis follow a specific hierarchy 1, 2:

  • Hepatocellular carcinoma (HCC): 44% of deaths, representing the leading cause 1
  • Liver failure: 49% across all cirrhotic patients 2
  • Variceal bleeding: 13% 2

Progression and Decompensation Risk

Understanding progression patterns is critical for risk stratification 1:

  • HCC develops at 3.9% annually and is the first complication in 27% of patients 1
  • Ascites develops at 2.9% annually and is the first complication in 14% of patients 1
  • 72% of patients remain Child-Pugh class A, while 21% progress to class B and 7% to class C during follow-up 1

Clinical Implications

Child-Pugh class A patients have substantially better prognosis than class B or C, with dramatic mortality differences in surgical contexts 3, 4, 5:

  • Class B mortality: 22.1% at 90 days postoperatively 3
  • Class C mortality: 54.5% at 90 days postoperatively 3
  • The threshold Child-Pugh score of ≤7 identifies patients who can safely undergo major surgery with 97% negative predictive value for mortality 4

Risk Stratification Factors

Significant predictors of death risk specifically in compensated (Child-Pugh class A) patients include 2:

  • Male sex
  • HBsAg positivity
  • Advanced age
  • Prothrombin time prolongation
  • Presence of esophageal varices

Patients with Child-Pugh class A cirrhosis should be monitored closely for HCC development, as this represents both the most common first complication and the leading cause of death in this population. 1

References

4
Research

Predicting outcome after cardiac surgery in patients with cirrhosis: a comparison of Child-Pugh and MELD scores.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004

Related Questions

What is the estimated mortality risk for a patient with Child-Pugh class B cirrhosis (liver dysfunction) undergoing an elective segmental colon resection for a benign polyp?
Can a patient with compensated (Child‑Pugh class A) liver cirrhosis be treated with Tremfya (guselkumab)?
Can upadacitinib (Janus kinase inhibitor) be given to patients with chronic liver disease (CLD) classified as Child-Pugh A?
How is the Child‑Pugh score calculated and used to stage chronic liver disease and guide prognosis and treatment decisions?
What is the 1-year survival rate for a cirrhosis patient with hepatitis B?
What are the indications, dosing regimen, administration method, monitoring parameters, and contraindications for intravenous iron sucrose?
What is the appropriate starting and maintenance dose of methimazole for an adult with newly diagnosed overt Graves’ disease?
What is the recommended treatment for an 8.17 mm subdural hematoma with diffuse cerebral edema?
What is the ten-year survival rate for an adult with compensated Child-Pugh class A cirrhosis?
Is cancer of the external auditory canal more common in the bony portion or the cartilaginous portion?
How should I manage a newly diagnosed hypertensive patient who presents with a subconjunctival hemorrhage?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question